Breast Cancer Management Guidelines

Introduction to Breast Cancer Guidelines

The American Society of Clinical Oncology (ASCO) recommends sentinel lymph node biopsy (SLNB) in early-stage breast cancer, with updated guidelines on axillary staging procedures 1

The American Society of Clinical Oncology (ASCO) suggests that postmenopausal women should receive a nonsteroidal aromatase inhibitor (AI) combined with a CDK4/6 inhibitor as first-line treatment for hormone receptor-positive, HER2-negative metastatic breast cancer 2
Premenopausal women require ovarian suppression or ablation combined with AI and CDK4/6 inhibitor for hormone receptor-positive, HER2-negative metastatic breast cancer 2
Endocrine therapy is preferred over chemotherapy except for immediately life-threatening disease or rapid visceral progression during adjuvant endocrine therapy, as recommended by the American Society of Clinical Oncology (ASCO) 3, 4

The American Society of Clinical Oncology (ASCO) recommends trastuzumab, pertuzumab, and taxane combination as the standard first-line therapy for HER2-positive metastatic breast cancer 5, 6
Trastuzumab emtansine (T-DM1) is recommended for second-line therapy after progression on first-line HER2-targeted treatment, according to the American Society of Clinical Oncology (ASCO) 6

The American Society of Clinical Oncology (ASCO) suggests that sequential single-agent chemotherapy is preferred over combination therapy for HER2-negative metastatic breast cancer, though combination regimens may be considered for symptomatic or immediately life-threatening disease 4, 7
Oral PARP inhibitor should be offered in first-through-third-line settings for patients with germline BRCA1/2 mutations rather than chemotherapy, as recommended by the American Society of Clinical Oncology (ASCO) 7

The American Society of Clinical Oncology (ASCO) recommends tamoxifen for 5 years as the standard adjuvant therapy for hormone receptor-positive male breast cancer 8
Men with hormone receptor-positive, HER2-negative metastatic disease should receive endocrine therapy as first-line treatment except for visceral crisis or rapidly progressive disease, according to the American Society of Clinical Oncology (ASCO) 8

Treatment should continue until unequivocal evidence of disease progression as documented by imaging, clinical examination, or disease-related symptoms, as recommended by the American Society of Clinical Oncology (ASCO) 3
Patients should be encouraged to enroll in clinical trials, including those receiving first-line treatment, according to the American Society of Clinical Oncology (ASCO) 3
Hormone therapy should be offered to patients whose tumors express any level of estrogen and/or progesterone receptors, as recommended by the American Society of Clinical Oncology (ASCO) 3